BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS
February 11, 2020 06:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
BrainStorm Issues 2019 Letter to Shareholders
December 18, 2019 05:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to...
BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site
November 25, 2019 06:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...